-transparent.png){kind=logo}
The value of clonidine (;Dixarit') for the prophylaxis of migraine has been assessed by a double blind cross-over trial. A dose of up to 0.15 mg daily was used. No effect on the frequency of the headaches could be detected over and above the 60 per cent reduction observed with a placebo. Severity, assessed subjectively by the patient, when it varied between placebo and clonidine, was less with clonidine (p<0.01). There was also some evidence that headaches lasting more than 12 hours were less common during treatment with the drug.
Related Publications
E I Adam, and
S M Gore, and
W H Price
February 1972,
Lancet (London, England),
E I Adam, and
S M Gore, and
W H Price
January 1980,
Pharmatherapeutica,
E I Adam, and
S M Gore, and
W H Price
October 1975,
Headache,
E I Adam, and
S M Gore, and
W H Price
May 1965,
The Journal of the College of General Practitioners,
E I Adam, and
S M Gore, and
W H Price
September 1975,
The New Zealand medical journal,
E I Adam, and
S M Gore, and
W H Price
April 1995,
Ugeskrift for laeger,
E I Adam, and
S M Gore, and
W H Price
December 1982,
Developmental medicine and child neurology,
E I Adam, and
S M Gore, and
W H Price
January 1970,
The British journal of clinical practice,
E I Adam, and
S M Gore, and
W H Price
January 1991,
The British journal of clinical practice,
E I Adam, and
S M Gore, and
W H Price
March 1976,
Acta neurologica Scandinavica,
